Analyst Michael Ulz from Morgan Stanley maintained a Buy rating on Mirum Pharmaceuticals and keeping the price target at $81.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Michael Ulz has given his Buy rating due to a combination of factors that highlight Mirum Pharmaceuticals’ strategic positioning and future prospects. Despite the recent filing by Sandoz for a generic version of Livmarli, Mirum’s management anticipated such a move and is prepared to defend its patents through a lawsuit, which will delay the approval of the generic drug for 30 months. This demonstrates Mirum’s proactive approach and confidence in its intellectual property portfolio.
Furthermore, the company is looking forward to the results of the Phase 2b trial for volixibat in the second quarter of 2026, which are expected to be positive. These developments, coupled with Mirum’s robust market capitalization and strategic planning, contribute to the positive outlook and justify the Buy rating. The company’s preparedness and strong defense against generic competition, along with promising pipeline developments, position it well for future growth.
According to TipRanks, Ulz is a 3-star analyst with an average return of 2.6% and a 43.71% success rate. Ulz covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Kyverna Therapeutics, Inc., and Alnylam Pharma.
In another report released on November 12, TD Cowen also maintained a Buy rating on the stock with a $95.00 price target.